Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach